Reata Pharmaceuticals, Inc.
RETA · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $4 | $3 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4 | $3 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 11,564.6% | -78.7% | 69.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 96.3% | 100% | 100% | 100% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 849.8% | -56,495.9% | -12,825.2% | -12,604.8% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 848.5% | -56,801% | -9,354.7% | -14,220.6% |
| EPS Diluted | 4.65 | -3 | -2.35 | -2.1 |
| % Growth | 255% | -27.7% | -11.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |